User: Guest  Login
Title:

S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI Imaging.

Document type:
Journal Article
Author(s):
Nipp, M; Elsner, M; Balluff, B; Meding, S; Sarioglu, H; Ueffing, M; Rauser, S; Unger, K; Höfler, H; Walch, A; Zitzelsberger, H
Abstract:
In papillary thyroid carcinoma (PTC), metastasis is a feature of an aggressive tumor phenotype. To identify protein biomarkers that distinguish patients with an aggressive tumor behavior, proteomic signatures in metastatic and non-metastatic tumors were investigated comparatively. In particular, matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry (IMS) was used to analyze primary tumor samples. We investigated a tumor cohort of PTC (n = 118) that were matched for age, tumor stage, and gender. Proteomic screening by MALDI-IMS was performed for a discovery set (n = 29). Proteins related to the discriminating mass peaks were identified by 1D-gel electrophoresis followed by mass spectrometry. The candidate proteins were subsequently validated by immunohistochemistry (IHC) using a tissue microarray for an independent PTC validation set (n = 89). In this study, we found 36 mass-to-charge-ratio (m/z) species that specifically distinguished metastatic from non-metastatic tumors, among which m/z 11,608 was identified as thioredoxin, m/z 11,184 as S100-A10, and m/z 10,094 as S100-A6. Furthermore, using IHC on the validation set, we showed that the overexpression of these three proteins was highly associated with lymph node metastasis in PTC (p < 0.005). For functional analysis of the metastasis-specific proteins, we performed an Ingenuity Pathway Analysis and discovered a strong relationship of all candidates with the TGF-?-dependent EMT pathway. Our results demonstrated the potential application of the MALDI-IMS proteomic approach in identifying protein markers of metastasis in PTC. The novel protein markers identified in this study may be used for risk stratification regarding metastatic potential in PTC.
Journal title abbreviation:
J Mol Med
Year:
2012
Journal volume:
90
Journal issue:
2
Pages contribution:
163-74
Language:
eng
Fulltext / DOI:
doi:10.1007/s00109-011-0815-6
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/21938494
Print-ISSN:
0946-2716
TUM Institution:
Institut für Allgemeine Pathologie und Pathologische Anatomie
 BibTeX